Executive Summary
A meta-analysis of 70,641 patients puts a sharp number on the durability gap for mitral TEER: 1-year mortality was 58% higher, reintervention nearly three-fold higher, and recurrent ≥3+ MR roughly five-fold higher after TEER versus surgical repair, with the recurrence gap widening to six-fold at three years. A Trends in Cardiovascular Medicine review of NOTION (10y), PARTNER 3 (7y), and Evolut Low Risk (6-7y) confirmed TAVR reintervention rates trending above SAVR in the newest low-risk data. A 5-year self-expanding TAVI cohort found no durability signal separating bicuspid from tricuspid AS. The EARLY TAVR treadmill registry (JAMA Cardiology) found 15% of "asymptomatic" severe AS patients had a positive stress test, and 20% of those still went untreated at one year — tightening the case for stress testing before calling anyone truly asymptomatic, and complicating the ESC's Class IIa push for early intervention across the board.
- TEER for MR carries a 4.80 RR of recurrent ≥3+ MR at 1 year and 6.51 RR at 3 years versus surgical repair in a 70,641-patient meta-analysis — durability is the fault line (Heart Lung Circ).
- Evolut Low Risk 6-7y data show higher TAVR reintervention than SAVR (9.8% vs 6.0%, P=0.02); NOTION and PARTNER 3 remain non-significant (Trends Cardiovasc Med).
- Failure-to-rescue rates after TAVR are identical at high- and low-volume centers (~11%) — the volume-outcome relationship is about avoiding complications, not saving people from them (JACC Cardiovasc Interv).
- Propensity-matched tricuspid data: T-TEER beat annuloplasty on residual TR ≤1+ (50.0% vs 34.2%) and complications (4.5% vs 27.0%) with equivalent 1-year mortality/HFH (JACC Advances).
- A novel CT-derived "Vectorial Angle" at the LVOT predicted post-TAVI pacemaker need (AUC 0.806) independent of membranous septal length (Am J Cardiol).
What to watch: Edwards Lifesciences reports Q2 earnings today (July 23) with EPS est $0.74 on $1.70B revenue — TAVR volume commentary will frame the read-through on early-intervention indication expansion.
Aortic Valve (TAVR/TAVI)
The long-term TAVR durability question got a sober update. A Trends in Cardiovascular Medicine review aggregating NOTION (10y), PARTNER 3 (7y), and Evolut Low Risk (6-7y) shows composite endpoints remain non-inferior, but the reintervention signal in Evolut Low Risk (9.8% TAVR vs 6.0% SAVR, P=0.02) is real and will only grow as follow-up matures. Neither ACC/AHA 2020 (SAVR preferred <65) nor ESC 2025 (SAVR preferred <70) is refuted by these data — if anything, the reintervention curve validates the surgical-preferred age floor. [NOTABLE] The EARLY TAVR treadmill registry in JAMA Cardiology found 15% of screened "asymptomatic" severe AS patients had positive stress tests, 80% of whom went to AVR — but 20% didn't, despite a Class I or IIa indication. Exercise testing works when applied; the field's failure is that it rarely is. A real-world 5-year self-expanding TAVI cohort (n=212 matched) found no BAV vs TAV difference in SVD (1.07% vs 1.79%) or BVF — but ACC/AHA 2020 and ESC 2025 both hold BAV TAVI at Class IIb, appropriately, given the small sample and absence of RCT data. On the procedural side, a novel CT-based Vectorial Angle predicted PPM need (AUC 0.806, N=67) — a small-N proof-of-concept pointing toward valve orientation relative to the conduction axis as the next frontier in preprocedural planning. A EJCTS state-of-the-art review pushed selective post-TAVI MDCT to detect subclinical leaflet thrombosis and prosthesis geometry — surveillance SAVR follow-up does not require.
Mitral Valve (MitraClip, PASCAL, TMVR)
[NOTABLE] The Heart Lung and Circulation meta-analysis of TEER vs surgical mitral repair (21 studies, 70,641 patients) is the day's most consequential paper. TEER recipients were older and sicker — but the 1-year mortality signal (RR 1.58), the three-fold reintervention rate, and the 4.80 RR of recurrent ≥3+ MR at 1 year, rising to 6.51 at 3 years, are not comorbidity artifacts. They are durability. ACC/AHA 2020 limits TEER to Class IIa for high-risk primary MR precisely because surgical repair achieves durable correction that TEER does not match; ESC 2025 holds the same Class IIa for primary MR, reserving its Class I upgrade for COAPT-eligible ventricular SMR where the comparator is medical therapy, not repair. This meta-analysis reinforces that expanding TEER beyond those carefully bounded criteria trades durability for procedural convenience. A JACC Case Reports piece on early single-leaflet device attachment after PASCAL TEER illustrates the same point at the case level: the anatomic complexity driving primary MR outruns the device, and conventional clocking strategies fail in complex anatomy.
Tricuspid Valve (TriClip, TTVR)
A JACC Advances propensity-matched comparison of T-TEER vs transcatheter annuloplasty (111 pairs from a 1,122-patient cohort) gave T-TEER a clear edge on acute TR reduction (residual ≤1+: 50.0% vs 34.2%; residual ≤2+: 87.7% vs 67.6%) and on procedural complications (4.5% vs 27.0%). One-year mortality/HFH was comparable (75.0% vs 79.8%, P=0.408) — insufficient follow-up to declare a winner, and the non-randomized, retrospective design biased toward centers with T-TEER volume limits inference. The finding sits inside the ESC 2025 Class IIa recommendation for transcatheter TV treatment in high-risk symptomatic severe TR; ACC/AHA 2020 has no equivalent recommendation. A separate Pacing and Clinical Electrophysiology case series surfaces an emerging downstream cost the trials have not quantified: patients needing PPM after tricuspid TEER require valve-sparing pacing strategies — leadless devices or LBBAP — a complication burden absent from the randomized trial composite endpoints.
Surgical vs. Transcatheter Comparisons
The surgical comparator wins on the merits today, not on guideline nuance. The TEER vs surgical mitral repair meta-analysis and the low-risk TAVR long-term review point in the same direction: transcatheter therapies deliver equivalent early outcomes and inferior durability as follow-up matures. The signal is stronger in mitral than aortic. Combined with the JACC Cardiovascular Interventions failure-to-rescue analysis (n≈500,000 TAVRs, 808 sites) showing FTR rates identical across volume tiers, the field faces a clear ceiling: complication avoidance is the lever, tied to case volume and preprocedural planning, not to rescue capacity once a complication occurs.
Device & Technology
Venus Medtech completed enrollment in the PREVAILS TAVR trial for the Venus-PowerX device, adding another self-expanding platform to the pipeline. The Vectorial Angle CT parameter is a small-N (67) proof-of-concept pointing to where preprocedural planning is heading: valve orientation relative to the conduction axis, not just implantation depth or membranous septal length. The EJCTS review on selective post-TAVI MDCT formalizes what many centers already practice — surveillance CT for leaflet thickening and geometry — and will grow in relevance as low-risk TAVR patients accumulate follow-up years.
Regulatory & Policy
TCTMD is running a two-part series from NY Valves on the proposed 2026 National Coverage Determination for TAVR, which will shape site volume requirements, operator credentialing, and whether the low-volume centers highlighted in the FTR analysis remain viable. A recall of steerable sheaths used in pulsed field ablation is adjacent to the valve space but relevant to the growing overlap between EP and structural procedures. Product-liability exposure is real: a new Sapien 3 lawsuit alleges iliac artery perforation causing wrongful death — vascular complications remain the residual safety story in transfemoral TAVR.
Financial Analysis
Edwards is a barometer for the entire early-intervention thesis. TD Cowen reiterated Buy on Edwards citing TAVR growth, and EARLY TAVR expanding into asymptomatic severe AS is the tailwind. The JAMA Cardiology treadmill data cut both ways: 15% of "asymptomatic" patients aren't truly asymptomatic, which supports EARLY TAVR's rationale, but also means the addressable market for genuinely asymptomatic AVR is smaller than the top-line ESC IIa recommendation implies. Boston Scientific trades at a 53% six-month drawdown; the market has repriced growth expectations across the sector. Watch Edwards Q2 today for TAVR unit volume and Sapien 3 Ultra RESILIA mix.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $84.37, down $0.18 (-0.21%); 6-month change +0.85%
- Market cap $48.6B; P/E trailing 45.61, forward 25.09; beta 0.85; 52-week range $72.30-$96.29
- Analyst target $99.00 (range $84-$110, 25 analysts); consensus Buy
- Earnings TODAY (Jul 23): EPS est $0.74, revenue est $1.70B
- The purest structural-heart play. EARLY TAVR readout and asymptomatic AS expansion drive the bull case; the JAMA Cardiology treadmill data support screening intensity, which supports volume.
Medtronic (MDT)
- Close $81.89, down $0.46 (-0.56%); 6-month change -17.42%
- Market cap $104.8B; P/E trailing 22.07, forward 12.79; beta 0.58; 52-week range $73.31-$106.33
- Analyst target $97.84 (range $78-$121, 25 analysts); consensus Buy
- Next earnings Sep 1: EPS est $1.39, revenue est $9.55B
- Evolut Low Risk 6-7y reintervention gap (9.8% vs 6.0% SAVR) is a durability overhang. The 5-year self-expanding BAV data help, but the RCT signal at 6+ years is the harder read.
Abbott (ABT)
- Close $100.57, up $0.90 (+0.90%); 6-month change -5.12%
- Market cap $175.2B; P/E trailing 32.23, forward 16.58; beta 0.61; 52-week range $81.97-$137.49
- Analyst target $118.67 (range $92-$135, 24 analysts); consensus Buy
- Next earnings Oct 14: EPS est $1.42, revenue est $13.00B
- MitraClip and TriClip franchises are exposed to today's mitral meta-analysis showing durability inferiority to surgical repair. Tricuspid data from the JACC Advances propensity match are supportive for T-TEER over annuloplasty.
Boston Scientific (BSX)
- Close $42.97, down $0.22 (-0.51%); 6-month change -53.55%
- Market cap $63.9B; P/E trailing 18.05, forward 11.57; beta 0.58; 52-week range $42.20-$109.50
- Analyst target $72.43 (range $55-$106, 28 analysts); consensus Strong Buy
- Next earnings Jul 29: EPS est $0.83, revenue est $5.37B
- Steep drawdown reflects a broader repricing, not a structural-heart-specific problem. ACURATE neo2 and the mitral pipeline remain the questions.
Anteris Technologies (AVR.AX)
- Close A$11.80, up A$0.10 (+0.85%); 6-month change +21.03%
- Market cap A$1.1B; forward P/E -5.41; beta 0.73; 52-week range A$4.84-$15.47
- DurAVR THV single-piece porcine leaflet story remains speculative but the equity is recovering.
Market outlook: The sector is bifurcated. Edwards trades as if TAVR volume growth is intact and asymptomatic AS is a real opportunity. Medtronic and Boston Scientific trade as if the growth thesis needs to be defended. Today's durability data — mitral in particular — support selectivity: transcatheter revenue growth depends on staying within guideline-defined populations, not indication creep.
Clinical Trial Updates
Aortic
- NCT07456280 — IMPROVE Study: Noninvasive ECG monitoring for early discharge in TAVI patients with conduction disorders. Status: Recruiting. Enrollment: 100. Sponsor: Hospital Universitari Vall d'Hebron Research Institute. Interventions: standard care vs PhysioMem PM 100 4G ambulatory monitoring. Last updated 2026-07-22. The post-TAVI conduction observation window has resisted standardization; the Vectorial Angle CT data published today confirm that PPM risk stratification remains unsolved.
Landmark trials to track: EARLY TAVR (asymptomatic severe AS, follow-up ongoing), TRILUMINATE, TRISCEND II, Tri.Fr, RESHAPE-HF2, DEDICATE, PARTNER 3 (7-year data now published), Evolut Low Risk (6-7 year data now published), NOTION (10-year data now published), REPAIR-MR, PRIMARY.
Looking ahead: Edwards Q2 tonight sets the near-term tone on TAVR volume growth and asymptomatic AS uptake. The durability signals published this week — mitral TEER at 1-3 years, TAVR at 6-10 years — will define how ACC/AHA and ESC calibrate their next revisions, and whether the ESC's Class I upgrade for TEER in ventricular SMR and its lowered age threshold for TAVI hold up when the next round of registry data arrives.